Scythian Announces ABP’s First Purchase Order

Scythian Biosciences (TSXV:SCYB; OTC:SCCYF) announced it’s soon to be completed acquisition, Argentina-based ABP received its first purchase order of cannabidiol (CBD) from Aphria (TSX:APH).

As quoted in the press release:

The Order is for Aphria’s renowned CBD oil strain, Rideau.

ABP’s first order will go to the Dr. Juan P. Garrahan Pediatric Hospital (the “Hospital”), a highly recognized and one of the most credible medical institutions in South America, to support a first of its kind clinical study focused on treating refractory epilepsy in children. The study, which will be conducted over 2.5 years, will also determine the product’s pharmacokinetics in order to optimize the dosage of future treatments. The study will include the participation and guidance of some of the top neurologists and pediatric specialists in the country. Additionally, with the support of Scythian and ABP, a training program will be conducted during and after the study to train and educate a network of specialized doctors across multiple provinces in the country using Aphria’s pharmaceutical grade medical cannabis.

Click here to read the full press release.

Source: globenewswire.com